Xolair 150 mg solution for injection in pre-filled syringe, Placebo, solution for injection in pre-filled syringe, BP11
BP11-301
Phase 3 small_molecule active
Quick answer
Xolair 150 mg solution for injection in pre-filled syringe, Placebo, solution for injection in pre-filled syringe, BP11 for Chronic Urticaria is a Phase 3 program (small_molecule) at CuraTeQ Biologics s.r.o with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CuraTeQ Biologics s.r.o
- Indication
- Chronic Urticaria
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active